Peter C. Fong
0000-0003-2689-8958
1 paper found
Refreshing results…
Pembrolizumab Plus Olaparib for Patients With Previously Treated and Biomarker-Unselected Metastatic Castration-Resistant Prostate Cancer: The Randomized, Open-Label, Phase III KEYLYNK-010 Trial
Missing publications? Search for publications with a matching author name.